Prospective Cohort of Patients With Intracerebral Hemorrhage

NCT ID: NCT06670456

Last Updated: 2024-11-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-11-06

Study Completion Date

2028-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators designed a multicentral, observational, prospective cohort study to provide cortical data for risk stratification and biomarkers on early outcomes, complications, long-term neurological function, and cognitive status of spontaneous intracerebral hemorrhage patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke, Acute Intracerebral Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with spontaneous intracerebral hemorrhage (ICH) through skull radiologic scans (CT or MRI);
* Underwent no surgical intervention;

Exclusion Criteria

* Secondary intracerebral hemorrhage (with leading cause, e.g., Moyamoya disease, arteriovenous malformation, intracranial aneurysm, tumor, brain trauma)
* Pre-stroke life expectancy \< 1 year for severe comorbidities (e.g., Progressive malignant tumor, severe chronic heart failure \[NYHA: III-IV\], severe chronic obstructive pulmonary disease \[III-IV\], chronic kidney disease requiring hemodialysis)
* Severe dependency or incorporation to interview (e.g., pre-stroke mRS\>3, severe dementia, intractable mental disease)
* Unsuitable for inclusion in the study in the opinion of the investigator
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fuzhou University

OTHER

Sponsor Role collaborator

Fujian Medical University

OTHER

Sponsor Role collaborator

National Institute of Hospital Administration (China)

UNKNOWN

Sponsor Role collaborator

De-zhi Kang

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

De-zhi Kang

Prof.

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

De-zhi Kang, MD

Role: PRINCIPAL_INVESTIGATOR

First Affiliated Hospital of Fujian Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China

Site Status RECRUITING

Anxi County Hospital

Quanzhou, Fujian, China

Site Status RECRUITING

Jinjiang Municipal Hospital

Quanzhou, Fujian, China

Site Status RECRUITING

The Second Affiliated lospital of Xiamen Medical College

Xiamen, Fujian, China

Site Status RECRUITING

Zhangzhou Municipal Hospital

Zhangzhou, Fujian, China

Site Status RECRUITING

Liaocheng People's Hospital

Liaocheng, Shandong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

De-zhi Kang, MD

Role: CONTACT

86 15759413951

Fu-xin Fu-xin, MD

Role: CONTACT

86 13600893154

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Fu-xin Lin, MD

Role: primary

86 13552358381

Yan Zheng

Role: backup

86 15659781312

Jian-cai Chen

Role: primary

86 13859736832

Nao-nan Weng

Role: backup

86 13506910771

Xie-li Guo

Role: primary

86 15960795588

Zhen Qi

Role: backup

86 15880886519

Jian-wu Long

Role: primary

86 13859934007

Chun Luo

Role: backup

86 15960802895

Wei-wei Wang

Role: primary

86 13806904186

Zhang Guo

Role: backup

86 13605011127

Wei-dong Liu

Role: primary

86 15806976699

Han-yu Sun

Role: backup

86 15910197887

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022ZD01003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Epidemiology of Intracerebral Hemorrhage
NCT06654544 NOT_YET_RECRUITING